FDA and the Reagan-Udall Foundation for the FDA invite you to a virtual public meeting on the potential medication error risks with investigational drug container labels. We are soliciting input from stakeholders (e.g., sponsors, investigators, clinical sites, entities that supply or label investigational drugs, and study participants) on the risk of medication errors related to the content and format of information on investigational drug container labels, the prevalence and nature of medication errors, and practices that might minimize the potential for such errors.
Each year, the Reagan-Udall Foundation for the FDA conducts an Annual Public Meeting of its Board of Directors to share its activities in support of the U.S. Food and Drug Administration. This free virtual meeting is open to the public, but advanced registration is required.
Join us for an interactive two-day workshop to discuss challenges around repurposing drugs that are already on the market but lack commercial and regulatory incentives for further research and development.
Expanded access programs, sometimes also called “compassionate use” programs, provide patients with serious or immediately life-threatening diseases or conditions access to investigational products outside of clinical tria